new psychoactive substances
|
|
- Magdalene Harrell
- 5 years ago
- Views:
Transcription
1 image courtesy of TicTac.org new psychoactive substances
2 new psychoactive substances New psychoactive substances (NPS) (designer drugs, research chemicals, legal highs ) have been emerging onto the recreational drug scene at an unprecedented rate. In parallel the number of substances notified to the Early Warning System (EWS) for the first time is increasing year on year; 13 in 2008, 24 in 2009, 41 in 2010, 49 in 2011 and 73 in It is predicted that this number will exceed 80 for Law enforcement, policy makers, scientists, clinicians, drug support workers and others actively working in this field are left floundering under the ingenuity of the market, and the speed at which it reacts. In general legislation has been effective in reducing use and availability of the controlled substance, but inadvertently spores a plethora of new compounds the substitution effect. As producers of designer drugs have become more creative, so have our methods for monitoring the emergence and usage of these substances. Since user reports are inherently unreliable and ingredients of legal highs are highly variable, analytically confirmed reports are critical for accurate information gathering. However, the availability of reference materials is frequently cited as a major challenge for those tasked with detection. Chiron strive to meet customer demand for NPS reference materials, and work closely with clinical and forensic institutions to this effect. This mini-catalogue lists a wide range of standards for NPS and associated substances [1]. [1] King, L.A. & Nutt, D.J. Deaths from legal highs : a problem of definitions, The Lancet, Volume 383, Issue 9921, Page 952, 15 March 2014, doi: /s (14) New psychoactive substance: a new narcotic or psychotropic drug, in pure form or in preparation, that is not controlled by the 1961 United Nations Single Convention on Narcotic Drugs or the 1971 United Nations Convention on Psychotropic Substances, but which may pose a public health threat comparable to that posed by substances listed in these conventions (Council Decision 2005/387/JHA). EMCDDA Definition
3 Amphetamines ME 100µg/mL K-ME 1000µg/mL DL-Amphetamine, Free base (+/-)-Amphetamine MG MG 50mg MG 100mg ME K-ME DL-Amphetamine Hydrochloride (+/-)-Amphetamine HCl MG MG 50mg MG 100mg MG DL-Amphetamine-d3 Hydrochloride (+/-)-Amphetamine-d3 HCl MG 50mg MG 100mg ME K-ME DL-Amphetamine-d5 Hydrochloride (+/-)-Amphetamine-d5 HCl MG MG 50mg MG 100mg (R)-(-)-Amphetamine Hydrochloride (S)-(+)-Amphetamine Hydrochloride DL-Amphetamine{ring13C6} Sulphate (+/-)-DL-Amphetamine{ring13C6} Sulphate ME ME ME 50µg Base/mL K-ME K-ME MG 5mg ME 100µg/mL DL-Acetylamphetamine (+/-)-Acetylamphetamine K-ME 1000µg/mL MG ME K-ME DL-Amphetamine Sulfate (+/-)-Amphetamine Sulfate MG MG 50mg MG 100mg ME DL-2-Bromoamphetamine Hydrochloride (+/-)-2-Bromoamphetamine HCl K-ME MG ME DL-3-Bromoamphetamine Hydrochloride (+/-)-3-Bromoamphetamine HCl K-ME MG ME DL-4-Bromoamphetamine Hydrochloride (+/-)-4-Bromoamphetamine HCl K-ME MG MG 50mg DL-4-Fluoroamphetamine DL-2-Fluoroamphetamine Hydrochloride DL-3-Fluoroamphetamine Hydrochloride (+/-)-4-Fluoroamphetamine (+/-)-2-Fluoroamphetamine HCl (+/-)-3-Fluoroamphetamine HCl ME ME ME 100µg/mL MG MG MG ME DL-2-Methoxyamphetamine Hydrochloride (+/-)-2-Methoxyamphetamine HCl K-ME MG ME DL-3-Methoxyamphetamine Hydrochloride (+/-)-3-Methoxyamphetamine HCl K-ME MG DL-2-Methylamphetamine Hydrochloride DL-3-Methylamphetamine Hydrochloride DL-4-Methylamphetamine Hydrochloride DL-PMA Hydrochloride (+/-)-2-Methylamphetamine HCl (+/-)-3-Methylamphetamine HCl (+/-)-4-MA, PMA, PAL-313, Aptol (+/-)-PMA HCl ME ME ME ME MG MG MG MG (+/-)-{13C6}-PMA Hydrochloride Ring-{13C6}-4-Methoxyamphetamine HCl ME 50µg Base/mL Methyl Amphetamines ME K-ME DL-Methamphetamine Hydrochloride (+/-)-Methamphetamine HCl MG MG 50mg MG 100mg DL-Methamphetamine-d3 Hydrochloride (+/-)-Methamphetamine-d3 HCl ME ME K-ME DL-Methamphetamine-d5 Hydrochloride (+/-)-Methamphetamine-d5 HCl MG MG 50mg MG 100mg DL-Methamphetamine{ring13C6} Hydrochloride (+/-)-Methamphetamine{ring13C6} HCl ME 50µg Base/mL MG 5mg ME (R)-(-)-Methamphetamine Hydrochloride K-ME MG ME (S)-(+)-Methamphetamine Hydrochloride K-ME MG DL-2-Fluoromethamphetamine Hydrochloride (+/-), DL-2-FMA HCl MG DL-3-Fluoromethamphetamine Hydrochloride (+/-), DL-3-FMA HCl MG ME DL-4-Fluoromethamphetamine Hydrochloride (+/-), DL-4-FMA HCl K-ME MG
4 Methyl Amphetamines Continued ME DL-2-Bromomethamphetamine Hydrochloride 1-(2-Bromophenyl)-N-methylpropan-2-amine HCl K-ME MG ME DL-3-Bromomethamphetamine Hydrochloride 1-(3-Bromophenyl)-N-methylpropan-2-amine HCl K-ME MG ME DL-4-Bromomethamphetamine Hydrochloride 1-(4-Bromophenyl)-N-methylpropan-2-amine HCl K-ME MG DL-2-Methoxymethamphetamine Hydrochloride DL-3-Methoxymethamphetamine Hydrochloride DL-4-Methoxymethamphetamine Hydrochloride (+/-), DL-2-MeOMA HCl, (+/-), DL-OMMA HCl (+/-), DL-3-MeOMA HCl, (+/-), DL-MMMA HCl (+/-)-PMMA HCl K-ME K-ME ME 100µg Acid/mL MG MG MG Ring-{13C6}-4-Methoxymethamphetamine Hydrochloride (+/-)-{13C6}-PMMA HCl ME 50µg Acid/mL DL-2-Methylmethamphetamine Hydrochloride DL-3-Methylmethamphetamine Hydrochloride (+/-), DL-2-MMA HCl (+/-), DL-3-MMA HCl K-ME K-ME MG MG DL-4-Methylmethamphetamine Hydrochloride (+/-), DL-4-MMA HCl (Free base) MG 3,4-Methylenedioxymethamphetamine ME (+/-)-MDMA Hydrochloride (+/-)-MDMA Hydrochloride-d5 3,4-Methylenedioxymethamphetamine HCl, Ecstasy HCl 3,4-Methylenedioxymethamphetamine HCl-D5, Ecstasy HCl-d K-ME MG MG 50mg MG 100mg ME K-ME MG MG 50mg MG 100mg D-MDMA Hydrochloride (+), D-3,4-Methylenedioxymethamphetamine, D-Ecstasy ME L-MDMA Hydrochloride (-), L-3,4-Methylenedioxymethamphetamine, L-Ecstasy ME (+/-)-{13C6}-MDMA Hydrochloride Ring-{13C6}-3,4- Methylenedioxymetamphetamine HCl ME 50µg Base/mL ME (+/-)-MDEA Hydrochloride 3,4-Methylenedioxyethylamphetamine HCl K-ME MG (+/-)-{13C6}-MDEA Hydrochloride ring-13c6-3,4-methylenedioxyethylamphetamine HCl ME 50µg Base/mL ME (+/-)-MDA Hydrochloride K-ME MG ME (+/-)-MDA Hydrochloride-d K-ME MG D-MDA Hydrochloride (+)-3,4-Methylenedioxyamphetamine HCl ME L-MDA Hydrochloride (-)-3,4-Methylenedioxyamphetamine HCl ME (+/-)-{13C6}-MDA Hydrochloride Ring-{13C6}-3,4-Methylenedioxyamphetamine HCl ME 50µg Base/mL Ephedrine (1R,2S)-(-)-Ephedrine ME 100µg/mL (1R,2S)-(-)-Ephedrine Hydrochloride G 1G (1R,2S)-(-)-Ephedrine-d6 Hydrochloride (dimethyl-d6) (1S,2R)-(+)-Ephedrine Hydrochloride ME ME MG G 5mg 1G (1S,2R)-(+)-Ephedrine-d3 Hydrochloride(N-methyl-d3) ME (1R,2S)-(-)-Norephedrine L-(-)-Norephedrine, L-(-)-Phenylpropylamine ME 100µg/mL MG DL-Norephedrine Hydrochloride MG 100mg (1R,2S)-(-)-N-Methylephedrine ME 100µg/mL (1S,2S)-(+)-Pseudoephedrine ME 100µg/mL (1S,2S)-(+)-Pseudoephedrine-d3 Hydrochloride (N-methyl-d3) ME (1R,2R)-(-)-Pseudoephedrine ME 100µg/mL (1R,2R)-(-)-Pseudoephedrine-d3 Hydrochloride (N-methyl-d3) ME D-Norpseudoephedrine Hydrochloride Cathine HCl ME MG
5 Cathinones (+/-)-Cathinone Hydrochloride Benzoylethanamine HCl ME MG (+/-)-Cathinone Hydrochloride-d MG BDB Benzodioxolylbutanamine, 1-(1,3-Benzodioxol-5- yl)butan-2-amine, MBDB metabolite MG Butylone Hydrochloride β-keto MBDB HCl MG Ethylone β-keto MDEA ME 100µg/mL MG 5mg 2-Fluoromethcathinone 2-FMC MG 4-Hydroxymethcathinone MG MBDB N-Methyl-1-(1,3-benzodioxol-5-yl)-2-aminobutane MG Methcathinone Hydrochloride ME MG 4-Methylethcathinone Hydrochloride 4-MEC HCl (Free base) MG 1mg ME Mephedrone Hydrochloride 4-Methylmethcathinone HCl MDPV Methylenedioxypyrovalerone, 1-(1,3-Benzodioxol- 5-yl)-2-(1-pyrrolidinyl)-1-pentanone HCl (Free base) α-pvp Hydrochloride α-pyrrolidinopentiophenone HCl K-ME MG MG 25mg K-ME MG ME MG 2C Phenethylamines ME 2C-B Hydrochloride 4-Bromo-2,5-dimethoxyphenethylamine HCl MG {13C6}-4-Bromo-2,5-dimethoxyphenethylamine Ring-{13C6}-2C-B Hydrochloride ME 50µg Base/mL HCl ME 2C-H Hydrochloride 2,5-Dimethoxyphenethylamine HCl MG Ring-{13C6}-2C-H Hydrochloride {13C6}-2,5-Dimethoxyphenethylamine HCl ME 50µg Base/mL ME 2C-I Hydrochloride 2,5-Dimethoxy-4-iodophenethylamine HCl MG Ring-{13C6}-2C-I Hydrochloride {13C6}-2,5-Dimethoxy-4-iodophenethylamine HCl ME 50µg Base/mL Bk-2C-B 2-Amino- 1- (4- bromo- 2, 5- dimethoxyphenyl) ethanone ME 100µg/mL K-ME 1000µg/mL MG 25C-NBOH Hydrochloride 2C-C-NBOH HCl MG ME 25C-NBOMe Hydrochloride 2C-C-NBOMe HCl, BOM 2C-C, Climbi K-ME MG MG 100mg 25E-NBOMe Hydrochloride 2C-E-NBOMe HCl, BOM 2C-E MG 100mg 2C-T-2 Hydrochloride 2,5-dimethoxy-4-ethylthiophenethylamine MG 100mg Indanes 2-AI MDAI MDAI Hydrochloride MMAI Hydrochloride 2-Aminoindane 5,6-Methylenedioxy-2-aminoindane 5,6-Methylenedioxy-2-aminoindane HCl 5-Methoxy-6-methyl-2-aminoindane HCl ME K-ME K-ME ME 100µg/mL 1000µg/mL K-ME MG MG K-ME 1000µg/mL Benzofuries (APBs and APDBs) 4-APB and 6-APB (Free base) 4- and 6-APB isomer mix / MG 5-APB Hydrochloride α-methyl-5-benzofuranethanamine HCl APB oxalate α-methyl-5-benzofuranethanamine oxalate, 5-(2-Aminopropyl)benzofuran oxalate (Free amine) 6-APB Hydrochloride α-methyl-6-benzofuranethanamine HCl EAPB 5- Benzofuranethanamine, N- ethyl- α- methyl EAPB 6- Benzofuranethanamine, N- ethyl- α- methyl ME K-ME ME K-ME MG ME K-ME MG ME 100µg/mL K-ME 1000µg/mL MG Please enquire
6 Piperazines Piperazine Benzoylpiperazine Benzoylpiperazine-2,2,3,3,5,5,6,6-d8 BZP BZP-D K-ME K-ME ME 1000µg/mL 1000µg/mL 100µg/mL G MG MG 1g ME 3-Chlorophenylpiperazine Hydrochloride m-cpp HCl K-ME MG ME 1-(2,5-Dimethoxybenzyl)piperazine Hydrochloride K-ME MG ME 1-(4-Fluorophenyl)piperazine dihydrochloride FPP K-ME MG para-fluorophenylpiperazine pfpp, 4-fluorophenylpiperazine, 4-FPP, fluoperazine MG 100mg 1-methyl-4-benzylpiperazine Hydrochloride MBZP HCl, Methylbenzylpiperazine HCl MG 100mg ME 100µg/mL 1-(3-Methylbenzyl)piperazine 3-MBZP K-ME 1000µg/mL MG ME 100µg/mL 1-(3-Methoxyphenyl)piperazine 3-MeOPP K-ME 1000µg/mL MG ME 100µg/mL 1-(4-Methoxyphenyl)piperazine 4-MeOPP K-ME 1000µg/mL MG ME 1-(2,3,4-Trimethoxybenzyl)piperazine dihydrochloride Trade name: Trimetazidine K-ME MG Synthetic Cannabinoids AB-PINACA ME 100µg/mL N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(pentyl K-ME 1000µg/mL 1H-indazole)-3-carboxamide MG AB-PINACA Metabolite (1-Pentyl-1H-indazole-3-carbonyl)-L-valine ME 100µg/mL 5F-AB-PINACA ME 100µg/mL N- (1- amino- 3- methyl- 1- oxobutan- 2- yl)- 1- ( K-ME 1000µg/mL fluoropentyl)- 1H- indazole- 3- carboxamide MG ME 100µg/mL AB-CHIMINACA K-ME 1000µg/mL MG AB-FUBINACA N-(4-Fluorobenzyl) analogue of AB-PINACA ME 100µg/mL AB-FUBINACA Metabolite (1-(4-Fluorobenzyl)-1H-indazole-3-carbonyl)-Lvaline ME 100µg/mL A-796,260 LTI-258, [1- [2- (4- morpholinyl)ethyl]- 1H- indol- 3- yl](2, 2, 3, 3- tetramethylcyclopropyl)- methanone MG ME 100µg/mL AB Adamantyl-[1-pentyl-1H-indol-3-yl]methanone K-ME 1000µg/mL MG ME 100µg/mL AB-005 [1- [(1- methyl- 2- piperidinyl)methyl]- 1H- indol K-ME 1000µg/mL yl](2, 2, 3, 3- tetramethylcyclopropyl)- methanone MG 5F-AKB48, APINACA 5-fluoropentyl analog, 5F ME 100µg/mL AKB-48-5F APINACA K-ME 1000µg/mL MG AM-694 AM-1248 AM-2201 [1- (5- fluoropentyl)- 1H- indol- 3- yl](2- iodophenyl) K-ME 1000µg/mL methanone MG ME 100µg/mL 1-Adamantyl-[1-[(1-methyl-2-piperidinyl)methyl] K-ME 1000µg/mL 1H-indol-3-yl]methanone MG ME 100µg/mL (1-Naphthalenyl)-(1-(5-fluoropentyl)-1H-indol K-ME 1000µg/mL MG AM Hydroxypentyl metabolite AM-2201 metabolite ME 100µg/mL AM Hydroxyindole metabolite AM-2201 main metabolite ME 50µg/mL MAM-2201 AM-2233 AM-2233 Hydrochloride APICA 5F-APICA APINACA (2-Iodophenyl)-[1-[(1-methyl-2-piperidinyl)methyl]- 1H-indol-3-yl]methanone, HCl ME 50µg/mL MG ME 100µg/mL K-ME 1000µg/mL MG MG ME 100µg/mL K-ME 1000µg/mL MG ME 100µg/mL K-ME 1000µg/mL MG ME 100µg/mL K-ME 1000µg/mL MG HU-308 4'-Methyl-AM-2201, [1- (5- Fluoropentyl)- 1H- indol- 3- yl](4- methyl- 1- naphthalenyl)- methanone (2-Iodophenyl)-[1-[(1-methyl-2-piperidinyl)methyl]- 1H-indol-3-yl]methanone SDB-001, 2NE1, JWH 018 adamantyl carboxamide STS-135, N-adamantyl-1-fluoropentylindole-3- Carboxamide AKB-48, N-Adamantyl-1-pentylindazole-3- carboxamide (C8)-CP 47,497 rel-5-(1,1-dimethyloctyl)-2-[(1r,3s)-3- hydroxycyclohexyl]phenol ME 100µg/mL HU-210 1,1-Dimethylheptyl-11-hydroxy-THC ME 100µg/mL 4- [4- (1, 1- dimethylheptyl)- 2, 6- dimethoxyphenyl]- 6, 6- dimethyl- bicyclo[3.1.1]hept- 2- ene- 2- methanol MG
7 Synthetic Cannabinoids Continued ME 100µg/mL JWH Pentyl-2-methyl-3-(1-naphthoyl)indole K-ME 1000µg/mL MG JWH-007 N-(5-Hydroxypentyl) metabolite JWH-007 N-(5-Hydroxypentyl) metabolite AN 50µg/mL Acetonitrile JWH-007 COOH JWH-007 PentylCOOH metabolite AN 50µg/mL Acetonitrile JWH-007 COOH-d4 JWH-007 PentylCOOH metabolite-d AN 50µg/mL Acetonitrile JWH-015 JWH-016 (2-Methyl-1-propyl-1H-idol-3-yl)-1- naphthenylmethanone 1-Butyl-2-methyl-3-(1-naphthoyl)indole K-ME 1000µg/mL MG 1000µg/mL ME 100µg/mL K-ME 1000µg/mL MG JWH-016 N-(4-hydroxybutyl) metabolite JWH-016 N-(4-Hydroxybutyl) metabolite AN 50µg/mL Acetonitrile JWH-016 COOH JWH-016 ButylCOOH metabolite AN 50µg/mL Acetonitrile JWH-016 COOH-d4 JWH-016 ButylCOOH metabolite-d AN 50µg/mL Acetonitrile JWH-018 JWH-018-d11 AM-678, 1-Naphthalenyl-(1-pentyl-1H-indol ME 50µg/mL ME 100µg/mL K-ME 1000µg/mL MG ME 100µg/mL MG 1-Naphthalenyl-(1-pentyl-1H-indol-3- -d11 JWH-018 N-(5-Hydroxypentyl) metabolite AN 50µg/mL Acetonitrile JWH-018 COOH JWH-018 N-Pentanoic acid metabolite AN 50µg/mL Acetonitrile JWH-018 COOH-d4 JWH-018 N-Pentanoic acid metabolite-d AN 50µg/mL Acetonitrile JWH-018 methylderivate (2-methylnaphthalene) (2-Methylnaphthalen-1-yl)-(1-pentyl-1H-indol K-ME 1000µg/mL MG JWH-018 Methylderivate N-(5-Hydroxypentyl) metabolite JWH-018 methylderivate N-(5-hydroxybutyl) metabolite AN 50µg/mL Acetonitrile ME 100µg/mL JWH Heptyl-3-(1-naphthoyl)indole K-ME 1000µg/mL MG ME 100µg/mL JWH Naphthalenyl-(1-pentylpyrrol K-ME 1000µg/mL MG JWH ME 100µg/mL 1- naphthalenyl(1- propyl- 1H- indol- 3- yl) ME 1000µg/mL methanone MG JWH-072-N-carboxy JWH-072 N-Propanoic acid metabolite AN 50µg/mL MG 5mg ME 50µg/mL JWH-073 (1-Butyl-1H-indol-3-yl)-1-naphthalenylmethanone ME 100µg/mL K-ME 1000µg/mL MG JWH-073-d9 (1-Butyl-1H-indol-3-yl)-1-naphthalenylmethanoned MG ME 100µg/mL JWH-073 N-(4-Hydroxybutyl) metabolite JWH-073 N-(4-Hydroxybutyl) metabolite AN 50µg/mL Acetonitrile JWH-073 COOH JWH-073 PentylCOOH metabolite, JWH 073 N-butanoic acid metabolite AN 50µg/mL Acetonitrile JWH-073 COOH-d4 JWH-073 PentylCOOH metabolite-d4, JWH 073 N-butanoic acid metabolite-d AN 50µg/mL Acetonitrile JWH-073 methylderivate (2-methylnaphthalene) 1-Butyl-3-(2-methyl-1-naphthoyl)indole K-ME 1000µg/mL MG JWH-073 methylderivate N-(4-Hydroxybutyl) metabolite JWH-073 Methylderivate N-(4-hydroxybutyl) metabolite AN 50µg/mL Acetonitrile JWH ME 100µg/mL K-ME 1000µg/mL MG JWH-081 COOH JWH-081 N-Pentanoic acid metabolite AN 50µg/mL Acetonitrile JWH-081 COOH-d4 JWH-081 N-Pentanoic acid metabolite-d AN 50µg/mL Acetonitrile JWH Pentyl-2-methyl-3-(4-methoxy-1- naphthoyl)indole ME 100µg/mL K-ME 1000µg/mL MG JWH-098 N-(5-Hydroxypentyl) metabolite JWH-098 N-(5-Hydroxypentyl) metabolite AN 50µg/mL Acetonitrile JWH-098 COOH JWH-098 N-Pentanoic acid metabolite AN 50µg/mL Acetonitrile JWH-098 COOH-d4 JWH-098 N-Pentanoic acid metabolite-d AN 50µg/mL Acetonitrile JWH-122 (4-Methoxyl-1-naphthalenyl)-(1-pentyl-1H-indol-3- (4-Methyl-1-naphthalenyl)-(1-pentyl-1H-indol ME 100µg/mL K-ME 1000µg/mL MG JWH-122-d11 (4-Methyl-1-naphthalenyl)-(1-pentyl-1H-indol-3- -d ME 100µg/mL JWH-122 N-(4-Hydroxypentyl)-metabolite AN 100µg/mL Acetonitrile JWH-122 N-(5-Hydroxypentyl)-metabolite AN 50µg/mL Acetonitrile JWH-122 COOH JWH-122 N-Pentanoic acid metabolite AN 50µg/mL Acetonitrile JWH-122 COOH-d4 JWH-122 N-Pentanoic acid metabolite-d AN 50µg/mL Acetonitrile JWH Hexyl-3-(1-naphthoyl)-5-phenyl-pyrrol MG JWH-200 JWH-203 WIN 55,225; (1-[2-(4-morpholinyl)ethyl]-1H-indol K-ME 1000µg/mL yl]-)-naphthalenylmethanone MG 2-(2-Chlorophenyl)-1-(1-pentyl-1H-indol-3-yl) K-ME 1000µg/mL ethanone MG JWH-203 N-(5-Hydroxypentyl) metabolite JWH-203 N-(5-Hydroxypentyl) metabolite AN 50µg/mL Acetonitrile JWH-203 COOH JWH-203 N-Pentanoic acid metabolite AN 50µg/mL Acetonitrile JWH-203 COOH-d4 JWH-203 N-Pentanoic acid metabolite-d AN 50µg/mL Acetonitrile JWH-210 (4-Ethylnaphthalene-1-yl)(1pentyl-1H-indol K-ME 1000µg/mL JWH-210 COOH JWH-210 N-Pentanoic acid metabolite AN 50µg/mL Acetonitrile JWH (2-Methoxyphenyl)-1-(1-pentyl-1H-indol-3-yl) K-ME 1000µg/mL ethanone MG JWH-250 N-(5-Hydroxypentyl) metabolite JWH-250 N-(5-Hydroxypentyl) metabolite AN 50µg/mL Acetonitrile JWH-250 COOH JWH-250 pentylcooh metabolite AN 50µg/mL Acetonitrile JWH-250 COOH-d4 JWH-250 metabolite-d AN 50µg/mL Acetonitrile JWH (2-Methylphenyl)-1-(1-pentyl-1H-indol-3-yl)- ethanone ME 50µg/mL Acetonitrile
8 Synthetic Cannabinoids Continued... JWH Pentyl-3-(1-naphthoyl)-5-(2-fluorophenyl)-pyrrol PB-22 QUPIC F-PB-22 5-fluoro QUPIC RCS ME 100µg/mL K-ME 1000µg/mL MG ME 100µg/mL K-ME 1000µg/mL MG ME 100µg/mL K-ME 1000µg/mL MG ME 100µg/mL K-ME 1000µg/mL MG RCS-4 N-(5-Hydroxypentyl) metabolite RCS-4 N-(5-Hydroxypentyl) metabolite AN 50µg/mL Acetonitrile RCS-4 COOH RCS-N-Pentanoic acid metabolite AN 50µg/mL Acetonitrile RCS-4 COOH-d4 RCS-N-Pentanoic acid metabolite-d AN 50µg/mL Acetonitrile RCS-4 ortho (2-Methoxyphenyl)-(1-pentyl-1H-indol K-ME 1000µg/mL MG RCS-4 ortho N-(5-Hydroxypentyl) metabolite RCS-4 ortho N-(5-Hydroxypentyl) metabolite AN 50µg/mL Acetonitrile RCS-4 ortho COOH RCS-4 ortho N-Pentanoic acid metabolite AN 50µg/mL Acetonitrile RCS-4 ortho COOH-d4 RCS-4 ortho N-Pentanoic acid metabolite-d AN 50µg/mL Acetonitrile RCS-4 meta (3-Methoxyphenyl)-(1-pentyl-1H-indol K-ME 1000µg/mL MG RCS-4 meta N-(5-hydroxypentyl) metabolite RCS-4 meta N-(5-Hydroxypentyl) metabolite AN 50µg/mL Acetonitrile RCS-4 meta COOH RCS-4 meta N-Pentanoic acid metabolite AN 50µg/mL Acetonitrile RCS-4 meta COOH-d4 RCS-4 meta N-Pentanoic acid metabolite-d AN 50µg/mL Acetonitrile RCS-4-4C (1-Butyl-1H-indol-3-yl)(4-methoxyphenyl) K-ME 1000µg/mL methanone MG RCS-8 1-(2-Cyclohexylethyl)-3-(2- methoxyphenylacetyl)indole MG UR-144 UR-144 N-(4-Hydroxypentyl) metabolite URB-597 URB ME 100µg/mL KM-X1 or (1-pentylindol-3-yl)-(2,2,3, K-ME 1000µg/mL tetramethylcycloprop MG ME 100µg/mL (1- (4- hydroxypentyl)- 1H- indol- 3- yl)(2, 2, 3, K-ME 1000µg/mL tetramethylcycloprop MG ME 100µg/mL KSD-4103, [3-(3-Carbamoylphenyl)phenyl] N K-ME 1000µg/mL cyclohexylcarbamate MG ME 100µg/mL 6- methyl- 2- [(4- methylphenyl)amino]- 1- benzoxazin K-ME 1000µg/mL 4- one MG WIN Pravadoline K-ME 1000µg/mL WIN mesylate XLR-11 4-hydroxy SR-19, BTM-4, (4-Methoxyphenyl)-(1-pentyl-1Hindol-3- (R)-(5-methyl-3-(morpholinomethyl)-2,3-dihydro- [1,4]oxazino[2,3,4-hi]indol-6-yl)(naphthalen-1- methanesulfonate (1- (5- fluoro- 4- hydroxypentyl)- 1H- indol- 3- yl)(2, 2, 3, 3- tetramethylcycloprop XLR-11 5-fluoro UR ME 100µg/mL K-ME 1000µg/mL MG ME 100µg/mL K-ME 1000µg/mL MG ME 100µg/mL Benzodiazepines Bentazepam Diclazepam 7-Chloro-5-(2-chlorophenyl)-1,3-dihydro-1-methyl- 2H-1,4-benzodiazepin-2-one Etizolam Flubromazepam Nifoxipam 3-hydroxyflunitrazepam Nimetazepam Trade name Erimin Phenazepam Hydroxyphenazepam Phenazepam metabolite Phenazepam 4-oxide Phenazepam metabolite Pyrazolam ME 100µg/mL K-ME 1000µg/mL MG ME 100µg/mL K-ME 1000µg/mL MG ME 100µg/mL K-ME 1000µg/mL MG MG 100mg ME 100µg/mL K-ME 1000µg/mL MG Please enquire ME 100µg/mL K-ME 1000µg/mL MG T 100µg/mL Toluene K-T 1000µg/mL Toluene MG MG 50mg MG 100mg T 100µg/mL Toluene K-T 1000µg/mL Toluene MG T 100µg/mL Toluene K-T 1000µg/mL Toluene MG ME 100µg/mL K-ME 1000µg/mL MG
9 Abused or designer pharmaceuticals ME 100µg/mL Desomorphine Krokodil, Dihydrodeoxymorphine MG Dimethylamylamine Hydrochloride DMAA, Methylhexaneamine MG 100mg Etaqualone Hydrochloride Aolon, Athinzone Gabapentin Trade name Neurontin Gabapentin-d (S)-(+)-Pregabalin Trade name Lyrica (S)-(+)-Pregabalin-d4 (aminomethyl d2; hexanoic acid-2,2-d2) ME MG 25mg K-ME 1000µg/mL mg 25mg mg 100mg G 1g K-ME 1000µg/mL MG 5mg MG ME 100µg/mL K-ME 1000µg/mL MG MG 50mg MG 100mg ME 100µg/mL K-ME 1000µg/mL MG MG 25mg K-ME MG ME MG ME 100µg/mL MG MG 200mg ME MG MG 200mg ME 100µg/mL MG ME MG 5mg ME 100µg/mL K-ME 1000µg/mL MG MG 100mg 3,4-CTMP 3,4-Dichloromethylphenidate MG 3,4-CTMP Hydrochloride 3,4-Dichloromethylphenidate HCl MG Propylhexedrine Hydrochloride Hexahydromethamphetamine, Benzedrex, Obesin MG Norpropylhexedrine Hydrochloride Hexahydroamphetamine MG ME O-Desmethyl cis-tramadol Hydrochloride Tramadol metabolite M K-ME MG 25mg O-Desmethyl tramadol-d6 (racemic) Tramadol metabolite M1-d ME 100µg/mL Hydroxybutyrates Sodium gammahydroxybutyrate GHB Na K-ME 1000µg/mL MG 100mg K-ME 1000µg/mL Sodium gammahydroxybutyrate-d6 GHB-d6 Na MG MG 100mg Sodium gammahydroxybutyrate-1,4-13c2 GHB-13C2 Na K-ME 1000µg/mL MG K-ME 1000µg/mL Butyrolactone GBL, gammabutyrolactone MG MG 100mg K-ME 1000µg/mL Butyrolactone-d6 GBL-d6, gammabutyrolactone-d MG MG 100mg Aryl Cyclohexylamines ME K-ME (+/-)-Ketamine Hydrochloride Trade names Ketanest, Ketaset, and Ketalar MG MG 50mg MG 100mg (S)-(+)-Ketamine Hydrochloride ME (+/-)-Norketamine Hydrochloride Ketamine metabolite ME Methoxetamine (MXE) Cyclohexanone, 2- (ethylamino) - 2- ( K-ME 1000µg/mL methanol methoxyphenyl) MG neat neat Phencyclidine Hydrochloride PCP, "Angel dust" MG Phencyclidine-d5 Hydrochloride ME MG Tryptamines & Related Compounds Methylphenidate Hydrochloride (threo) Ritalin Methylphenidate-d9 Hydrochloride (piperidine-d9), (erythro+threo) Ritalinic acid Hydrochloride (threo) Ritalin-d Ritalinic acid (threo) (Free base) Ritalinic acid (erythro) Ritalinic acid-d9 Hydrochloride (piperazine-d9) (erythro+threo) Ethylphenidate α- Phenyl-2- piperidineacetic acid ethyl ester AMT α-mt, Indopan, α-methyltryptamine Please enquire N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]-Nmethylpropan-2-amine MG K-ME 1000µg/mL 5-MeO-MiPT 4-Acetylpsilocin fumarate 4-AcO-DMT, psilacetin MG
10 Plant Chemicals Salvinorin A MG ME 100µg/mL (-)-Scopolamine hydrobromide trihydrate Trade names Levo-duboisine, Hyosine MG 100mg MG (+/-)-Cathinone Hydrochloride Benzoylethanamine ME (+/-)-Cathinone Hydrochloride-d MG MG Cathine Hydrochloride D-Norpseudoephedrine HCl ME Other Materials Prolintane Prolintane Nitracaine (R)-(-)-Bromodragonfly Hydrochloride MT-45 Hydrochloride AH-7921 AH-7921-d6 (dimethyl-d6) 1c6, (+)-1-Cyclohexyl-4-( ME diphenylethylpiperazine) HCl MG 5mg 3, 4- Dichloro- N- [[ ME 100µg/mL (dimethylamino) cyclohexyl] methyl] benzamide K-ME 1000µg/mL 3, 4- Dichloro- N- [[ ME 100µg/mL (dimethylamino) cyclohexyl] methyl] benzamide-d K-ME 1000µg/mL ME 100µg/mL Diphenidine K-ME 1000µg/mL MG 10MG Methoxyphenidine ME 100µg/mL (±)-1-[1-(2-Methoxyphenyl) K-ME 1000µg/mL phenylethyl]piperidine MG 2-Methiopropamine 2- Thiopheneethanamine, N, α- dimethyl ME 100µg/mL MG Methiopropamine Hydrochloride MPA HCl MG MG 10MG 4-Methyl-4-methylaminorex p-methyl-4mar MG 3-Diethylamino-2,2-dimethylpropyl-4- nitrobenzoate, 4-nitro-dimethocaine (αr)-8-bromo-α-methyl-benzo[1,2-b:4,5-b']difuran- 4-ethanamine HCl ME 100µg/mL K-ME 1000µg/mL MG ME 100µg/mL K-ME 1000µg/mL MG 10MG ME
11 For ordering and information about prices and delivery in your country please contact your local distributor: NPS _v1, 05-14
THE EXPANDING REACH OF THE DESIGNER DRUG MOVEMENT IN 2011: CHALLENGES FOR FORENSIC TOXICOLOGY & CHEMISTRY
THE EXPANDING REACH OF THE DESIGNER DRUG MOVEMENT IN 2011: CHALLENGES FOR FORENSIC TOXICOLOGY & CHEMISTRY Barry K Logan PhD, DABFT, National Director Forensic Services, NMS Labs Willow Grove PA History
More informationResults from the STRIDA project. Matilda Bäckberg PhD, M.Sc.Pharm The Swedish Poisons Information Centre
Results from the STRIDA project Matilda Bäckberg PhD, M.Sc.Pharm The Swedish Poisons Information Centre Email: Matilda.Backberg@gic.se No. of calls Statistics from telephone service 1800 Amfetamin Amphetamine
More informationE/CN.7/2015/CRP.10 * * 9 December English only V (E) * The present document is reproduced in the form in which it was received.
9 December 2015 English only Commission on Narcotic Drugs Reconvened fifty-eighth session Vienna, 9-11 December 2015 Agenda item 6 Implementation of the international drug control treaties: Changes in
More informationSynthetic Drug Threats in the United States: 2018 Update
Synthetic Drug Threats in the United States: 2018 Update JILL M. HEAD SPECIAL TESTING AND RESEARCH LABORATORY DRUG ENFORCEMENT ADMINISTRATION Objectives 1. Overview of the DEA Emerging Trends & Reference
More informationList Name Chemical Name/AKA Type of drug Notes Substances emerging pre-2010: highlighted compounds are allegedly currently sold online in UK 6-APB
List Name Chemical Name/AKA Type of drug Notes Substances emerging pre-2010: highlighted compounds are allegedly currently sold online in UK 6-APB 6-(2-aminopropyl)benzofuran Benzo Fury Structurally similar
More informationNational Drug Early Warning System (NDEWS) Texas Sentinel Community Site Appendix Data Tables, 2015 NDEWS Coordinating Center
National Drug Early Warning System (NDEWS) Texas Sentinel Community Site Appendix Data Tables, 2015 NDEWS Coordinating Center Table 1: Demographic and Socio-Economic Characteristics, 2009-2013, ACS Table
More informationNovel psychoactive substances in postmortem toxicology. Pirkko Kriikku, PhD Forensic Toxicologist
Novel psychoactive substances in postmortem toxicology Pirkko Kriikku, PhD Forensic Toxicologist Postmortem toxicology in Finland Population: 5.5 million Deaths: ~51 000 per year Medico-legal cause-of-death
More informationForensic Toxicology Findings in DRDs. Dr Hazel Torrance Manager of the Forensic Toxicology Service Forensic Medicine and Science
Forensic Toxicology Findings in DRDs Dr Hazel Torrance Manager of the Forensic Toxicology Service Forensic Medicine and Science Forensic Toxicology at the University of Glasgow Dept of Forensic Medicine
More informationReports of advisory bodies
EXECUTIVE BOARD EB136/48 Rev.1 136th session 22 January 2015 Provisional agenda item 15.1 Reports of advisory bodies Expert committees and study groups 1 Report by the Secretariat EXPERT COMMITTEE ON DRUG
More informationSPICE Prevention Issues Measures in Switzerland in the fight against new drugs such as SPICE and bath salts
SPICE Prevention Issues 2012 Measures in Switzerland in the fight against new drugs such as SPICE and bath salts Werner Bernhard, Lars Ambach, Wolfgang Weinmann Institute of Forensic Medicine, University
More informationFinal Adjusted Aggregate Production Quotas for Schedule I and II Controlled
This document is scheduled to be published in the Federal Register on 11/03/2017 and available online at https://federalregister.gov/d/2017-24009, and on FDsys.gov Billing Code 4410-09-P DEPARTMENT OF
More informationZCPT S. Jog Rd. Suite Greenacres, FL Phone: (561)
ZCPT 4300 S. Jog Rd. Suite 540171 Greenacres, FL 33454 : (561) 343-0789 : ZCPT@ZCLabServices.com Official Use Only Client ID: Toxicology Proficiency Testing Order Form Institution Name (Please Print) CLIA
More informationFinal Adjusted Aggregate Production Quotas for Schedule I and II Controlled
This document is scheduled to be published in the Federal Register on 10/25/2016 and available online at https://federalregister.gov/d/2016-25696, and on FDsys.gov Billing Code 4410-09-P DEPARTMENT OF
More informationOverview and Limitations About Selected Data Sources Found in NDEWS Sentinel Community Site Profile Appendix Data Tables
Overview and Limitations About Selected Data Sources Found in NDEWS Sentinel Community Site Profile Appendix Data Tables August 2015 NDEWS Coordinating Center NDEWS is funded under NIDA Cooperative Agreement
More informationSEWPROF Roundtable Spain
SEWPROF Roundtable Spain John Ramsey TICTAC Communications Ltd St. George s, University of London London SW17 0RE TICTAC s contribution ER Dr. Bram Miserez Discovery and characterisation of NPS Test purchases
More informationCentral Asia Synthetic Drugs Situation Assessment. A Report from the UNODC Global SMART Programme
Central Asia Synthetic Drugs Situation Assessment A Report from the UNODC Global SMART Programme December 2017 CONTENTS PREFACE 3 GENERAL ABBREVIATIONS 4 CHEMICAL ABBREVIATIONS 5 EXPLANATORY NOTES 6 EXECUTIVE
More informationNational Drug Early Warning System (NDEWS) Los Angeles County Sentinel Community Site Appendix Data Tables, 2015
National Drug Early Warning System (NDEWS) Los Angeles County Sentinel Community Site Appendix Data Tables, 2015 NDEWS Coordinating Center Table 1: Demographic and Socio-Economic Characteristics, 2009-2013,
More informationSubstances under Surveillance
Substances under Surveillance The following substances are under surveillance by the World Health Organization (WHO) as they are considered to have the potential to cause public health harm. For ease of
More informationSynthetic Drugs: Overview and Issues for Congress
Synthetic Drugs: Overview and Issues for Congress Lisa N. Sacco Analyst in Illicit Drugs and Crime Policy Kristin Finklea Specialist in Domestic Security August 15, 2014 Congressional Research Service
More informationDrugs and The Internet
Issue 2, March 2014 Funded by the Australian Government under the Substance Misuse Prevention and Service Improvement Grants Fund Product of: The National Illicit Drug Indicators Project Recommended Van
More informationIn accordance with Article 10 of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances
EMCDDA Europol 2014 Annual Report on the implementation of Council Decision 2005/387/JHA In accordance with Article 10 of Council Decision 2005/387/JHA on the information exchange, risk assessment and
More information9889/15 JV/np/tt 1 DG D 2C
Council of the European Union Brussels, 15 June 2015 (OR. en) 9889/15 CORDROGUE 46 FOPOL 152 SAN 185 NOTE From: To: Europol and EMCDDA Delegations No. prev. doc.: 11072/14 Subject: EMCDDA-Europol 2014
More informationThe Challenges of Analytical Method Validation for Hallucinogens and Designer Stimulants in Biological Samples Using LC-TOF
The Challenges of Analytical Method Validation for Hallucinogens and Designer Stimulants in Biological Samples Using LC-TOF Barry K Logan, Ph.D., NMS Labs National Director, Forensic Services Goals The
More informationTrends and Patterns of Amphetamine-type Stimulants and New Psychoactive Substances
The Challenge of Synthetic Drugs in East and South-East Asia Global SMART Programme 2017 Trends and Patterns of Amphetamine-type Stimulants and New Psychoactive Substances Acknowledgements The Challenge
More informationNPS New Psychoactive Substances
NPS New Psychoactive Substances NPS are drugs that are synthetically designed to replicate the effects of illegal substances. People may refer to these drugs as legal highs, but many of the substances
More informationConventional and emerging drugs of abuse: the current situation
Conventional and emerging drugs of abuse: the current situation NEW PSYCHOACTIVE SUBSTANCES -THE HIGHS AND LOWS Maritim Hotel, Munich, 12-13 November 2015 Michael Uhl Director of Chemistry Unit Bavarian
More informationNew Psychoactive Substances (NPS)
New Psychoactive Substances (NPS) Reference materials 2018 LGC Quality ISO 9001 ISO/IEC 17025 ISO Guide 34 GMP/GLP ISO 13485 ISO/IEC 17043 Science for a safer world LGC is a global leader in measurement
More informationHealth Chapter ALABAMA STATE BOARD OF HEALTH ALABAMA DEPARTMENT OF PUBLIC HEALTH ADMINISTRATIVE CODE CHAPTER CONTROLLED SUBSTANCES
Health Chapter 420-7-2 ALABAMA STATE BOARD OF HEALTH ALABAMA DEPARTMENT OF PUBLIC HEALTH ADMINISTRATIVE CODE CHAPTER 420-7-2 CONTROLLED SUBSTANCES TABLE OF CONTENTS 420-7-2-.01 Authority 420-7-2-.02 Definitions
More informationChanging patterns of new and emerging psychoactive substances in Australia
Changing patterns of new and emerging psychoactive substances in Australia Prepared by Rachel Sutherland, on behalf of the Drug Trends team The Drug Trends program is supported by funding from the Australian
More informationDrug Threats in the United States: 2019 Update
Drug Threats in the United States: 209 Update J I L L M. H E A D S P E C I A L T E S T I N G A N D R E S E A R C H L A B O R AT O R Y D R U G E N F O R C E M E N T A D M I N I S T R AT I O N Objectives.
More informationDesigner Drugs / Research Chemicals / Legal Highs - A survey of recent seizures and an attempt to a more effective handling from a Swiss perspective
Toxichem Krimtech 2011;78(Special Issue):167 Designer Drugs / esearch Chemicals / Legal ighs - A survey of recent seizures and an attempt to a more effective handling from a Swiss perspective Michael Bovens,
More informationThe Challenge of New Psychoactive Substances (NPS) A Presentation for CAD by Dr Des Corrigan October 2015
The Challenge of New Psychoactive Substances (NPS) A Presentation for CAD by Dr Des Corrigan October 2015 New Psychoactive Substances Any substance, natural or synthetic which can produce stimulation or
More informationThis form should be completed and sent to:
International Narcotics Control Board FORM B/P ASSESSMENT OF ANNUAL MEDICAL AND SCIENTIFIC REQUIREMENTS FOR SUBSTANCES IN SCHEDULES II, III AND IV OF THE CONVENTION ON PSYCHOTROPIC SUBSTANCES OF 1971 (to
More informationINTER-AMERICAN DRUG ABUSE CONTROL COMMISSION C I C A D
INTER-AMERICAN DRUG ABUSE CONTROL COMMISSION C I C A D Secretariat for Multidimensional Security FIFTY-FIFTH REGULAR SESSION April 29 - May 1, 2014 Washington, D.C. OEA/Ser.L/XIV.2.55 CICAD/doc.2106/14
More informationNational Drug Early Warning System (NDEWS) Sentinel Community Site (SCS) Drug Use Patterns and Trends: SCS Data Tables
National Drug Early Warning System (NDEWS) Sentinel Community Site (SCS) Drug Use Patterns and Trends: SCS Data Tables The SCS Data Tables are prepared by NDEWS Coordinating Center staff and include information
More informationSynthetic Drug Abuse Prevention Act of A look at how this new legislation is written and how it will affect the narcotics investigator.
What s Inside Volume 3 (August, 2012) Synthetic Drug Abuse Prevention Act of 2012 A look at how this new legislation is written and how it will affect the narcotics investigator. Cathinone Chemical Classes
More informationSynthetic Drugs: Overview and Issues for Congress
Synthetic Drugs: Overview and Issues for Congress Lisa N. Sacco Analyst in Illicit Drugs and Crime Policy Kristin Finklea Specialist in Domestic Security May 3, 2016 Congressional Research Service 7-5700
More informationEcstasy and Related Drugs Reporting System: 2016 Findings
Ecstasy and Related Drugs Reporting System: 16 Findings EMCDDA Lisbon Sept 19 th - th Courtney Breen and Amanda Roxburgh on behalf of the Drug Trends Team Drug Trends aims: Document the price, purity,
More information5923/07 ZH/mp 1 DG H II A
COUNCIL OF THE EUROPEAN UNION Brussels, 7 February 2007 5923/07 CORDROGUE 13 COVER NOTE from : Europol and EMCDDA to : Horizontal Working Party on Drugs Subject : EMCDDA-Europol 2006 Annual Report on the
More informationNew psychoactive substances in Belgium: current status
New psychoactive substances in Belgium: current status P. Blanckaert Coordinator Belgian Early Warning System on Drugs Rue Juliette Wytsmanstraat 14 1050 Brussels Belgium T +32 2 642 54 08 F +32 2 642
More informationSmartNotes. Why test for synthetic cannabinoids? Synthetic Cannabinoids Facts
DIAGNOSTICS Synthetic Cannabinoids SmartNotes Why test for synthetic cannabinoids? Synthetic Cannabinoids Facts Largest group of New Psychoactive Substances (NPS) on the market Mind-altering chemicals
More informationNational Drug Early Warning System (NDEWS,
April 18, 217 CENTER FOR SUBSTANCE ABUSE RESEARCH United States Sentencing Commission Synthetic Cannabinoids, Cathinones, and MDMA Written Testimony: Eric D. Wish, PhD, CESAR Director* CESAR 4321 Hartwick
More informationHydroxyitraconazole, 100 μg/ml H-110 Hydroxyitraconazole-D 4. , 100 μg/ml H MeO-DiPT, 1.0 mg/ml M-167 Metronidazole-D 3
Cerilliant s new product development process goes beyond just putting a product on the shelf. From synthesis design to performing accelerated and real-time stability studies, our products are designed
More informationSYNTHETIC CANNABINOIDS BILL STATUS REPORT CARRYOVER, 2014, SPECIAL SESSIONS, AND PROPOSED REGULATIONS
SYNTHETIC CANNABINOIDS BILL STATUS REPORT CARRYOVER,, SPECIAL SESSIONS, AND PROPOSED REGULATIONS Research current through June 19,. This project was supported by Grant No. G1399ONDCP03A, awarded by the
More informationRecent developments in the detection of harms arising from the use of synthetic cathinonesin Europe
No conflict of interest Recent developments in the detection of harms arising from the use of synthetic cathinonesin Europe Ana Gallegos 24 September 2015 Lisbon Addictions Conference 2015 Paper session
More informationWHO Expert Committee on Drug Dependence. Thirty-seventh report
W H O T e c h n i c a l R e p o r t S e r i e s 998 WHO Expert Committee on Drug Dependence Thirty-seventh report The World Health Organization was established in 1948 as a specialized agency of the United
More informationAPPROVED REGULATION OF THE STATE BOARD OF PHARMACY. LCB File No. R Effective October 31, 2017
APPROVED REGULATION OF THE STATE BOARD OF PHARMACY LCB File No. R011-17 Effective October 31, 2017 EXPLANATION Matter in italics is new; matter in brackets [omitted material] is material to be omitted.
More informationAlcohol. Ethanol Highlands Parkway, Suite 100 Smyrna, GA 30082
Alcohol The alcohol of interest is ethanol. Ethanol has a sedative effect in the brain. Ethanol intoxication symptoms include blurred vision, slurred speech, poor coordination and difficulty thinking depending
More informationSynthetic Drugs: Overview and Issues for Congress
Synthetic Drugs: Overview and Issues for Congress Lisa N. Sacco Analyst in Illicit Drugs and Crime Policy Kristin Finklea Acting Section Research Manager and Specialist in Domestic Security September 16,
More informationUnderestimated impact of novel psychoactive substances: laboratory confirmation of recreational drug toxicity in Oslo, Norway
Underestimated impact of novel psychoactive substances: laboratory confirmation of recreational drug toxicity in Oslo, Norway Odd Martin Vallersnes 1,2, Per Sverre Persett 3, Elisabeth Leere Øiestad 4,5,
More informationThe EU Early Warning System: 20 years of monitoring New Psychoactive Substances in Europe
The EU Early Warning System: 20 years of monitoring New Psychoactive Substances in Europe Rachel Christie, PhD NDEWS webinar: Examining Global Drug Early Warning Systems, Part 4: Monitoring Drug Trends
More informationPROPOSED REGULATION OF THE BOARD OF PHARMACY LCB FILE NO. R048-18I. The following document is the initial draft regulation proposed
PROPOSED REGULATION OF THE BOARD OF PHARMACY LCB FILE NO. R048-18I The following document is the initial draft regulation proposed by the agency submitted on 03/15/2018 1 Proposed Regulation of the Nevada
More informationNational Drug Early Warning System (NDEWS) Sentinel Community Site (SCS) Drug Use Patterns and Trends: SCS Snapshot
National Drug Early Warning System (NDEWS) Sentinel Community Site (SCS) Drug Use Patterns and Trends: SCS Snapshot The SCS Snapshot is prepared by NDEWS Coordinating Center staff and contains graphics
More informationSYNTHETIC CANNABINOIDS BILL STATUS REPORT CARRYOVER, 2014, SPECIAL SESSIONS, AND PROPOSED REGULATIONS
SYNTHETIC CANNABINOIDS BILL STATUS REPORT CARRYOVER,, SPECIAL SESSIONS, AND PROPOSED REGULATIONS Research current through May 13,. This project was supported by Grant No. G1299ONDCP03A, awarded by the
More informationINTER-AMERICAN DRUG ABUSE CONTROL COMMISSION C I C A D
1 INTER-AMERICAN DRUG ABUSE CONTROL COMMISSION C I C A D Secretariat for Multidimensional Security FIFTY-SECOND REGULAR SESSION November 28-30, 2012 San José, Costa Rica OEA/Ser.L/XIV.2.52 CICAD/doc.1988/12
More informationAnnual report 2012: the state of the drugs problem in Europe
Annual report 2012: the state of the drugs problem in Europe Ilze Jekabsone, MD, MPH Reitox and international cooperation unit 14 December 2012 2 Setting the scene After 30+ years with heroin centre stage
More informationNational Drug Early Warning System (NDEWS) Sentinel Community Site (SCS) Drug Use Patterns and Trends: SCS Snapshot
National Drug Early Warning System (NDEWS) Sentinel Community Site (SCS) Drug Use Patterns and Trends: SCS Snapshot The SCS Snapshot is prepared by NDEWS Coordinating Center staff and contains graphics
More informationDetection of synthetic cannabinoids in hair
Detection of synthetic cannabinoids in hair Alberto Salomone Lisbon, 28 th May 2015 Rise of NPS Arise of critical situations Acute intoxication Workplace testing Driving re-licensing Anti-doping analyses
More informationMinneapolis/St. Paul, Minnesota Drug Abuse Trends: January 2014 Update
Minneapolis/St. Paul, Minnesota Drug Abuse Trends: January 2014 Update Carol Falkowski Drug Abuse Dialogues ABSTRACT Heroin and other opiate addiction continued to escalate in the Twin Cities in 2013.
More informationProposal for a COUNCIL DECISION
EUROPEAN COMMISSION Brussels, 12.1.2018 COM(2018) 31 final 2018/0011 (NLE) Proposal for a COUNCIL DECISION on the position to be adopted, on behalf of the European Union, in the sixty-first session of
More informationPROPOSED REGULATION OF THE STATE BOARD OF PHARMACY LCB FILE NO. R011-17
PROPOSED REGULATION OF THE STATE BOARD OF PHARMACY LCB FILE NO. R011-17 Workshop April 13, 2017 Explanation Language in bold blue italics is new; language in red text [omitted material] is language to
More informationPROPOSED REGULATION OF THE STATE BOARD OF PHARMACY. LCB File No. R015-13
PROPOSED REGULATION OF THE STATE BOARD OF PHARMACY LCB File No. R015-13 Proposed Amendments to NAC 453.510 Purpose of Proposed Amendment: Add certain synthetic cannabis or spice drugs to Schedule I. NAC
More informationThis form should be completed and sent to:
International Narcotics Control Board FORM B/P ASSESSMENT OF ANNUAL MEDICAL AND SCIENTIFIC REQUIREMENTS FOR SUBSTANCES IN SCHEDULES II, III AND IV OF THE CONVENTION ON PSYCHOTROPIC SUBSTANCES OF 1971 (to
More informationDesigner Drugs Is Your Drug Testing Program Keeping Up? 2
The challenges detecting the latest advent of designer drugs has become a moving target. With the increasing number of new compounds entering the United States every year, law enforcement and treatment
More informationNational Drug Early Warning System (NDEWS) Sentinel Community Site (SCS) Drug Use Patterns and Trends: SCS Snapshot
National Drug Early Warning System (NDEWS) Sentinel Community Site (SCS) Drug Use Patterns and Trends: SCS Snapshot The SCS Snapshot is prepared by NDEWS Coordinating Center staff and contains graphics
More informationProposal for a COUNCIL DECISION
EUROPEAN COMMISSION Brussels, 1.12.2014 COM(2014) 716 final 2014/0340 (NLE) Proposal for a COUNCIL DECISION on subjecting 4-methyl-5-(4-methylphenyl)-4,5-dihydrooxazol-2-amine (4,4'-DMAR) and 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine
More informationNew drugs in Europe, 2012
ISSN 1977-7841 New drugs in Europe, 2012 EMCDDA Europol 2012 Annual Report on the implementation of Council Decision 2005/387/JHA 2012 New drugs in Europe, 2012 EMCDDA Europol 2012 Annual Report on the
More informationProposal for a COUNCIL DECISION
EUROPEAN COMMISSION Brussels, 31.8.2016 COM(2016) 548 final 2016/0262 (NLE) Proposal for a COUNCIL DECISION on subjecting the new psychoactive substance methyl 2-[[1-(cyclohexylmethyl)-1Hindole-3-carbonyl]amino]-3,3-dimethylbutanoate
More informationDrug Checking: l esperienza ed i dati. Alberto SALOMONE
Drug Checking: l esperienza ed i dati Alberto SALOMONE NIGHTLIFE NPS REPLACEMENT EXTASY: Synthetic cathinones LSD: NBOMe series HEROIN: fentanyl and analogs DRUG CHECKING STRATEGY SAMPLE unknown substance
More informationNational Drug Early Warning System (NDEWS) Sentinel Community Site (SCS) Drug Use Patterns and Trends: SCS Data Tables
National Drug Early Warning System (NDEWS) Sentinel Community Site (SCS) Drug Use Patterns and Trends: SCS Data Tables The SCS Data Tables are prepared by NDEWS Coordinating Center staff and include information
More information9668/15 JV/PN/np 1 DGD2C
Council of the European Union Brussels, 9 June 2015 (OR. en) Interinstitutional File: 2014/0183 (NLE) 9668/15 CORDROGUE 42 NOTE From: To: Presidency Delegations No. Cion doc.: 16240/14 Subject: Draft Council
More informationDEPARTMENT OF HEALTH IN THE MATTER ORDER FOR SUMMARY ACTION THE SALE AND DISTRIBUTION OF SYNTHETIC CANNABINOIDS
V.. - STATE OF NEW YORK : ---------- DEPARTMENT OF HEALTH IN THE MATTER OF THE SALE AND DISTRIBUTION OF SYNTHETIC CANNABINOIDS --------- x ORDER FOR SUMMARY ACTION v WHEREAS, a cannabinoid is a class of
More informationClinical Toxicology: An Update
Clinical Toxicology: An Update Dr. Shaun Greene VICTORIAN POISONS INFORMATION CENTRE AND AUSTIN HOSPITAL CLINICAL TOXICOLOGY SERVICE Drug Abuse in Australasia VICTORIAN POISONS INFORMATION CENTRE AND AUSTIN
More informationNOT FOR HUMAN CONSUMPTION
HARMFUL NOT FOR PRESENTATION TO ANYONE UNDER 18 NOT FOR HUMAN CONSUMPTION Benzodiazepines Diazepam Estazolam Etizolam Flunitrazepam Clorazepate Flutoprazepam Phenazepam Tetrazepam Nimetazepam Nordazepam
More informationPrimer on Synthetic Opioids I/S Brian Dempsey
Primer on Synthetic Opioids I/S Brian Dempsey 412-777-6945 brian.w.dempsey@usdoj.gov Sources - ACOME - Overdose Free PA Website - Pennsylvania Opioid Overdose Reduction Technical Assistance Center (TAC)
More informationSynthetic Drugs and Natural Substances
Synthetic Drugs and Natural Substances Pat Pizzo Director of Toxicology Alere Toxicology Services The world leader in serving science Who am I? Director of Toxicology at Alere In the field for 47 years
More informationSUBSTANCE MISUSE PROGRAMME. Drug deaths in Wales 2017
SUBSTANCE MISUSE PROGRAMME Drug deaths in Wales 2017 About Public Health Wales Public Health Wales exists to protect and improve health and wellbeing and reduce health inequalities for people in Wales.
More informationEMCDDA Europol 2009 Annual Report on the implementation of Council Decision 2005/387/JHA
EMCDDA Europol 2009 Annual Report on the implementation of Council Decision 2005/387/JHA In accordance with Article 10 of Council Decision 2005/387/JHA on the information exchange, risk-assessment and
More information10/1/2010. Accredited by ASCLD/LAB International Standard (ISO/IEC 17025) ASCLD/LAB Supplemental. Quality Systems Manual SWGDRUG. Section Methods/SOPs
Drug Chemistry Section Susan Gross Forensic Science Supervisor Minnesota BCA Drug Chemistry Section - Who we are - What we do - Goals of section - Statistics - Trends Who we are MN Bureau of Criminal Apprehension
More informationWEDINOS Headlines 6,452. wedinos.org 5,806 BULLETIN. Samples. received. Samples. received. Samples. analysed. Samples. rejected
BULLETIN Issue 11 - Jan - Mar 2017 WEDINOS Quarterly Newsletter Collecting, Testing, Informing wedinos.org WEDINOS Headlines TOTAL number of samples received by WEDINOS October 2013 to March 2017 The WEDINOS
More informationDrugs of abuse. Africa Health 23
Drugs of abuse Simon L Hill Simon HL Thomas Abstract Toxicity related to drug misuse is a common reason for hospital presentation. The recent emergence of substantial numbers of novel psychoactive substances
More informationGLOBAL S MART UPDATE. Understanding the synthetic drug market: the NPS factor VOLUME 19. March
GLOBAL S MART UPDATE VOLUME 19 March Understanding the synthetic drug market: the NPS factor EN ES Research 2018 GLOBAL SMART UPDATE About the SMART Update Synthetic drugs constitute one of the most significant
More informationBULLETIN WEDINOS
WEDINOS Quarterly Newsletter Issue 4 Oct-Dec 2014 BULLETIN Collecting, Testing, Inorming wedinos.org The WEDINOS project has been designed or the collection and testing o substances and, most importantly,
More informationNational Drug Early Warning System (NDEWS) Sentinel Community Site (SCS) Drug Use Patterns and Trends: SCS Snapshot
National Drug Early Warning System (NDEWS) Sentinel Community Site (SCS) Drug Use Patterns and Trends: SCS Snapshot The SCS Snapshot is prepared by NDEWS Coordinating Center staff and contains graphics
More informationAN ACT relating to drugs and declaring an emergency. Be it enacted by the General Assembly of the Commonwealth of Kentucky:
AN ACT relating to drugs and declaring an emergency. Be it enacted by the General Assembly of the Commonwealth of Kentucky: Section 1. KRS 218A.010 is amended to read as follows: (1) "Administer" means
More informationA review of the collision induced dissociation fragmentation and the metabolism of synthetic cathinone derivatives
A review of the collision induced dissociation fragmentation and the metabolism of synthetic cathinone derivatives Nichola Cunningham A thesis submitted in fulfilment of the requirements for the degree
More informationRisk Assessment of Psychoactive Substances: Potentialities and Limitations
Risk Assessment of Psychoactive Substances: Potentialities and Limitations Leslie A. King, MSc, PhD ReDUse Conference, Vienna, 16 November 2012 1 Overview Why and how risk assessments on psychoactive substances
More informationEMCDDA Europol 2010 Annual Report on the implementation of Council Decision 2005/387/JHA
EMCDDA Europol 2010 Annual Report on the implementation of Council Decision 2005/387/JHA In accordance with Article 10 of Council Decision 2005/387/JHA on the information exchange, risk-assessment and
More informationEMCDDA Europol 2009 Annual Report on the implementation of Council Decision 2005/387/JHA
EMCDDA Europol 2009 Annual Report on the implementation of Council Decision 2005/387/JHA In accordance with Article 10 of Council Decision 2005/387/JHA on the information exchange, risk-assessment and
More informationObjectives. Why new drugs? New drugs of abuse: synthetic cannabinoids, stimulants, and 10/14/2015. Describe several new drugs of abuse
New drugs of abuse: synthetic cannabinoids, stimulants, and more Robert G. Hendrickson, MD Professor, Emergency Medicine, OHSU Program Director, Medical Toxicology Fellowship Associate Medical Director,
More information2014 Key Australian findings: psychostimulant drug market
214 Key Australian findings: psychostimulant drug market Natasha Sindicich & Lucy Burns National Drug Trends Conference Maritime museum, Sydney Monday, 2 th October, 214 Funded by the Australian Government
More informationLisa Booze, PharmD, CSPI
Lisa Booze, PharmD, CSPI Psychoactive drugs created to avoid existing laws Modify existing drugs or new drugs with different chemical structures >200 new drugs and 8 classes of drugs since 2009 80 new
More informationCrime and Justice. New Psychoactive Substances Evidence Review
Crime and Justice New Psychoactive Substances Evidence Review NEW PSYCHOACTIVE SUBSTANCES EVIDENCE REVIEW Fiona Fraser, Safer Communities Analytical Unit, Scottish Government Scottish Government Social
More informationEMCDDA Europol 2011 Annual Report on the implementation of Council Decision 2005/387/JHA
EMCDDA Europol 2011 Annual Report on the implementation of Council Decision 2005/387/JHA In accordance with Article 10 of Council Decision 2005/387/JHA on the information exchange, risk assessment and
More informationabout methodology of monitoring and selecting the web shops see methodology on trend.eu/).
Substance briefing: 6-APB This technical folder provides information on 6-APB. The information provided is based on a number of existing data sources and work undertaken as part of the I-TREND project.
More informationSubstance briefing: MPPP
Substance briefing: MPPP This technical folder provides information on MPPP. The information provided is based on a number of existing data sources and work undertaken as part of the I-TREND project. Research
More informationThe European Early-warning system on new drugs. Dr. R. Sedefov & D. Lopez, Ancona, 18 September 2009
The European Early-warning system on new drugs Dr. R. Sedefov & D. Lopez, Ancona, 18 September 2009 This presentation A brief introduction to the EMCDDA and EWS What have we learned? The concept of new
More informationVILLAGE OF OBLONG, ILLINOIS ORDINANCE NO O-567
VILLAGE OF OBLONG, ILLINOIS ORDINANCE NO. 2015-O-567 AN ORDINANCE TO AMEND CHAPTER 27, DIVISION IV OFFENSES INVOLVING DRUGS SYNTHETIC ALTERNATIVE DRUGS OF THE REVISED CODE OF ORDINANCES OF THE VILLAGE
More informationPills, Powders, Potions and Paraphernalia
Pills, Powders, Potions and Paraphernalia A P R N 2 0 1 6 C N F E R E N C E W E D N E S D A Y, F E B R U A R Y 1 7, 2 0 1 6 C H A R L E S T N, S C D E M I G A R V I N, B S, P H A R M. D., R. P h., F -ABFT
More information